Trial Profile
Contribution of Endothelin-1 to Exercise Intolerance in HF
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs PMZ-2123 (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- 30 Apr 2019 Status changed from recruiting to completed.
- 15 Nov 2018 Planned primary completion date changed from 1 Sep 2018 to 31 Mar 2019.
- 21 Nov 2017 Planned End Date changed from 1 Sep 2018 to 1 Sep 2019.